BioLineRx Ltd.
BLRXBioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Drugs in Pipeline
10
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
BL-8040 1.25 mg/kg + G-CSF
Multiple Myeloma
horse anti-thymocyte globulin (hATG)
Aplastic Anemia
BL-7040
Ulcerative Colitis
Morphine
Acute Pain
BL - 1020
Schizophrenia
BL 1020 High Dose
Schizophrenia
Ara-C
Acute Myeloid Leukemia
BL-8040
Metastatic Pancreatic Adenocarcinoma
BL-1020
Schizophrenia
BL-7010
Celiac Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BL-8040 1.25 mg/kg + G-CSF | Phase 3 | Multiple Myeloma | - | - |
horse anti-thymocyte globulin (hATG) | Phase 2 | Aplastic Anemia | - | - |
BL-7040 | Phase 2 | Ulcerative Colitis | - | - |
Morphine | Phase 2 | Acute Pain | - | - |
BL - 1020 | Phase 2 | Schizophrenia | - | - |
BL 1020 High Dose | Phase 2 | Schizophrenia | - | - |
Ara-C | Phase 2 | Acute Myeloid Leukemia | - | - |
BL-8040 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
BL-1020 | Phase 2 | Schizophrenia | - | - |
BL-7010 | Phase 2 | Celiac Disease | - | - |